viewInnoCan Pharma

Innocan Pharma says clinical trials demonstrate the effectiveness of SHIR line of CBD skincare products

Results indicated significant hydration increases for each two-, four-, eight, and 24-hour period after application

InnoCan Pharma -
The SHIR facial serum contains 300 milligrams of CBD

Innocan Pharma Corporation (CSE:INNO) said Tuesday that clinical studies have demonstrated the effectiveness of the firm’s SHIR CBD facial serum on skin hydration.

The study looked at the impact of SHIR, which contains 300 milligrams of CBD, on hydration levels by measuring the skin capacitance periodically up to 24 hours after the serum was applied.

Results indicated significant hydration increases for each two-, four-, eight, and 24-hour period after application, according to a release from Innocan. In addition, the serum was well tolerated with no uncomfortable symptoms reported by participants.

READ: Innocan Pharma strikes deal to distribute its SHIR line of CBD beauty products in Italy and Switzerland

All of the SHIR Derma Cosmetic products tested to date have demonstrated to be non-irritating in clinical testing, according to Israel-based Innocan.

CEO Iris Bincovich told investors that the results demonstrate the efficacy of the product.

"Hydrating the skin is one of the most crucial measures to keep the skin healthy, young and also to eliminate wrinkles,” Bincovich said in a statement.

“The amazing results of the new clinical studies are in addition to Innocan's research and development efforts to bring to market, a trustworthy product that will set a new industry standard.”

SHIR skincare products combine the benefits of CBD with the most effective ingredients in an innovative formula to deliver visible results.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: InnoCan Pharma

Price: 0.3 CAD

Market: CSE
Market Cap: $52.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...


Innocan Pharma received U.S. FDA approval for their over the counter CBD...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has just received FDA approval in the United States for their patent-pending CBD Relief &GO pain relief collection. Bincovich talks about the collection and when they would...

on 07/20/2020

2 min read